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Abstract
While our previous studies suggest that limiting bleomycin-induced complement activation 
suppresses TGF-β signaling, the specific hierarchical interactions between TGF-β and 
complement in lung fibrosis are unclear. Herein, we investigated the mechanisms underlying TGF-
β-induced complement activation in the pathogenesis of lung fibrosis. C57-BL6 mice were given 
intratracheal instillations of adenoviral vectors overexpressing TGF-β (Ad-TGFβ) or the firefly 
gene-luciferase (Ad-Luc; control). Two weeks later, mice with fibrotic lungs were instilled RNAi 
specific to receptors for C3a or C5a-C3ar or C5ar, and sacrificed at day 28. Histopathological 
analyses revealed that genetic silencing of C3ar or C5ar arrested the progression of TGF-β-
induced lung fibrosis, collagen deposition and content (hydroxyproline, col1a1/2); and 
significantly suppressed local complement activation. With genetic silencing of either C3ar or 
C5ar, in Ad-TGFβ-injured lungs: we detected the recovery of Smad7 (TGF-β inhibitor) and 
diminished local release of DAF (membrane-bound complement inhibitor); in vitro: TGF-β-
mediated loss of DAF was prevented. Conversely, blockade of the TGF-β receptor prevented C3a-
mediated loss of DAF in both normal primary human alveolar and small airway epithelial cells. Of 
the 52 miRNAs analyzed as part of the Affymetrix array, normal primary human SAECs exposed 
to C3a, C5a or TGF-β caused discrete and overlapping miRNA regulation related to epithelial 
proliferation or apoptosis (miR-891A, miR-4442, miR-548, miR-4633), cellular contractility 
(miR-1197) and lung fibrosis (miR-21, miR-200C, miR-31HG, miR-503). Our studies present 
potential mechanisms by which TGF-β activates complement and promotes lung fibrosis.
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Introduction
Idiopathic Pulmonary Fibrosis (IPF) is a devastating disease characterized by progressive 
scarring of the lung. The architectural remodeling has long been debated as a process 
involving multiple alveolar epithelial injuries which triggers a number of chronic 
inflammatory signals which in turn drives dysregulated tissue repair. TGF-β has emerged as 
the undisputed master regulator of fibrosis which triggers a number of other pro-fibrotic 
signals which serve as a feed-forward loop and augment lung remodeling. Additionally, a 
number of other inflammatory signals trigger the autocrine synthesis of TGF-β in the lung. 
Studies from our lab demonstrate two different inflammatory signaling cascades, i.e. IL-17A 
[1] and the complement cascade [2] which trigger TGF-β-related signaling pathways. Our 
recent report also suggests that IL-17A may drive fibrosis via the complement cascade [3]. 
Signaling interactions between these pro-fibrotic pathways may shed significant insights on 
the specific drivers of epithelial injury and dysregulated tissue repair.
The complement cascade has been implicated in IPF [2,4-6] as well as several other 
autoimmune diseases, including chronic lung allograft rejection [7], renal transplant [8] and 
allergic asthma [9]. The complement cascade is an integral arm of innate immunity with the 
components C3a and C5a being the major players in epithelial injury. Studies have also 
implicated a role for microRNAs in epithelial injury [10] and TGF-β-driven lung fibrosis 
[11-14]. MicroRNAs are post-transcriptional gene regulators that function by binding to 
specific sequences, typically in the 39-untranslated region of the target mRNAs and blocking 
translation or causing the rapid degradation of the target transcript [15]. Interestingly, studies 
that have been reported on C3a or C5a-driven miRNA regulation in causing epithelial injury 
or lung fibrosis are lacking.
In this study, we examined the hierarchical relationship of TGF-β and the complement 
cascade in driving the pathogenesis of lung fibrosis. In our prior report [4], we had shown 
that limiting complement activation by blocking the receptors for C3a or C5a attenuates 
systemic TGF-β activity and local TGF-β-related transcriptional signaling. Therefore, it is 
not known if the complement cascade is upstream of TGF-β. We thus hypothesized that if 
the complement cascade is upstream then there will not be any protection against direct 
TGF-β-induced lung fibrosis. However, if there is some protection then that would indicate 
that these pathways are parallel and share mechanisms that drive lung fibrosis. To address 
these questions, we utilized the adenoviral vector-mediated overexpression of TGF-β in 
order to induce lung fibrosis and blocked the complement cascade therapeutically using 
siRNA sequences specific to C3ar and C5ar. We then performed a series of experiments 
utilizing the murine lung tissues from our murine model and normal primary human airway 
and alveolar epithelial cells to further address mechanisms in vitro.
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Materials and Methods
Cell culture conditions and reagents
Normal primary human alveolar type II epithelial cells (hAECs; Cell Biologics, Chicago, 
IL) were grown in human alveolar epithelial basal media supplemented with serum and 
growth factors (Cell Biologics). The cells were seeded at 70% confluence and incubated in 
5% CO2-95% air. Before stimulation, cells were growth arrested using basal media alone for 
1 h. Normal primary human small airway epithelial cells (SAECs; Clonetics, Cambrex 
Biosciences, Walkersville, MD) from five different donor lungs were grown in small airway 
basal media supplemented with growth factors (Clonetics). Before stimulation, cells were 
growth arrested using 0.01% serum or 1:100 growth factors containing media for 1h. These 
studies used recombinant human C3a and C5a (100 nM; Complement Technology, Inc., 
Tyler, TX), platelet-derived TGF-β1 (2 ng/ml; Roche Diagnostics, Germany). Antagonists 
against C3aR (2.5 μM; C3aRA-SB290157) and ALK5 (2.5 μM; ALK5 In-SB431542) were 
purchased from Calbiochem, EMD Millipore, Billerica, MA. All other reagents were from 
Sigma.
Animal studies
The Animal Care and Use Committee at the Indiana University School of Medicine 
approved the animal protocols used in this study. C57-BL6 mice (female, 8 weeks; Jackson 
Laboratories, Bar Harbor, ME) were anesthetized by intraperitoneal injections of a mixture 
of ketamine hydrochloride (10 mg/kg) and xylazine (150 mg/kg). After adequate 
anaesthesia, approximately 40 μl of suspension containing 1 × 109 PFU of adenoviral 
vectors overexpressing TGF-β1 (ViraQuest, North Liberty, IA) or the firefly gene-luciferase 
(Welgen Inc., Worcester, MA) [1] were delivered intratracheally. The mice were placed 
under observation until they recovered consciousness. Mice were monitored daily for 
adverse reactions and changes in behaviour.
RNA interference (RNAi) studies
For in vivo oropharyngeal RNAi delivery, single-duplex small interference RNA (siRNA) 
sequences targeting C3aR and C5aR [4] (50 μg; Sigma), or non-targeting control siRNA (50 
μg; Dharmacon Technologies, Pittsburgh, PA) were used. For in vitro RNAi transfection in 
hSAECs, single duplexes siRNA sequence targeting C3aR or C5aR or non-targeting control 
siRNA (100 nM; Sigma) were transfected using Oligofectamine (Invitrogen, Foster City, 
CA) for 24 h. Subsequently, the transfected cells were cultured in basal media with 1:100 
growth factors for 16 h followed by treatment.
Western blotting
Cell lysates of primary normal human small airway epithelial cells (hSAECs) and alveolar 
type II epithelial cells (hAECs) and acellular BALF were analyzed for equal protein 
concentrations and then subjected to immunoblotting as previously described [1-4,16,17]. 
Antibodies used were against C3aR [3], and C5aR [3] were purchased from Novus 
Biologicals, Littleton, CO. CD46 [2] and DAF [3] antibodies were purchased from Santa 
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Cruz Biotechnology. Densitometric analyses were performed with ImageJ 1.32j (NIH, 
Bethesda, MD).
Hydroxyproline content of whole lung
We homogenized mouse whole lungs in PBS and then acidified (by adding an equal volume 
of 12 N HCl), hydrolyzed (by heating at 120°C for 24 h), and processed samples for 
hydroxyproline measurements as previously described [18].
Real-time polymerase chain reaction (qPCR)
Total RNA was isolated from cells and whole lung homogenates with the RNeasy Mini Kit 
(Qiagen, Valencia, CA) and reverse transcribed with qScript cDNA SuperMix (Quanta 
BioSciences Inc., Foster City, CA). Real-time PCR was performed for each cDNA using 
Taqman Assays (Applied Biosystems, Inc., Foster City, CA). The semi-quantitative real-time 
PCR data for each target gene are expressed as 2-Ct relative quantitation vs. endogenous 
control, with error bars representing the standard error.
ELISA
Acellular BALF derived from mice treated with the siRNA-specific to C3aR or C5aR, were 
used to measure the soluble form of C5b-9 using Terminal Complement Complex C5b9 
BioassayTM ELISA kit (mouse), (US Biological Lifesciences Inc., Salem, MA), as per 
manufacturer’s protocol. The active forms of C3a and C5a were measured in the BALF 
using Mouse complement fragment 3a ELISA kit and Mouse complement fragment 5a 
ELISA kit (MyBiosource, San Diego, CA) respectively, as per manufacturer’s protocol.
Affymetrix analysis
SAECs derived from five different normal lungs were exposed to C3a or C5a (100 nM) or 
TGF-β1 (2 ng/ml) for 24 h. RNA was isolated, and the quality of the total RNA was verified 
by the Nanodrop (Fisher Scientific, Inc.) by measuring the 260/280 absorbance ratio and 
confirming that this ratio is at 1.7 and above. cDNA was subjected to Affymetrix analysis by 
the Microarray Core, Indiana University School of Medicine to perform gene expression 
profile analysis on Affymetrix HG-U133 Plus 2.0 Arrays, following the manufacturer’s 
recommendations. Differentially expressed genes were then identified with the rank product 
method. This method, based on the statistical analysis of the expression rank of each gene in 
the replicate experiments, has been shown [6] to perform especially well for heterogeneous 
donor lung derived data and low number of replicates. The method produces an estimate of 
the false discovery rate (FDR) based on a randomization procedure. Differential expression 
is defined by the statistical analysis (false discovery rate <0.01) by fold-ratio comparing the 
agonists to the control in each of the five different normal cells used and the fold change was 
set at ± 1.5. These statistical analyses were performed by the core facility.
Statistical analysis
Statistical analysis was performed using Student’s t test and one-way ANOVA with 
Bonferroni as the post hoc test using GraphPad Prism version 4.03 for Windows, GraphPad 
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Software (San Diego, CA, www.graphpad.com); unless otherwise stated. Statistical 
significance was defined at ‘p’<0.05.
Results
RNA-interference specific to C3ar or C5ar arrests the progression of TGF-β-induced lung 
fibrosis
We had reported elevated local C3a and C5a in clinical [2] and experimental lung fibrosis 
[4]. Our prior studies indicate an induction of C3aR and C5aR expression in lung epithelial 
cells in response to TGF-β [2]; and in mesenchymal cells in response to C3a or C5a [4]. We 
also reported that C3a and C5a each induce mRNA expression of TGF-β and suppress that 
of Smad7 [2]. Further, blockade of C3aR and C5aR expression mitigated the progression of 
bleomycin-induced lung fibrosis by suppressing local TGF-β-related signaling and systemic 
TGF-β activity [4]. We next sought to determine whether this reduction in TGF-β activity is 
responsible for the protection, or simply an arrest in bleomycin-induced lung fibrosis lowers 
TGF-β activity and signaling. We hypothesized that if genetic silencing of C3ar or C5ar 
arrests the progression of lung fibrosis via the reduction in systemic TGF-β activity and 
local TGF-β-related mRNA expression, then this protection should be reversed in fibrotic 
environment driven by TGF-β. Towards this end, we employed an adenoviral vector 
overexpressing TGF-β in mice. Adenoviral overexpression of TGF-β has induced lung 
fibrosis in monkeys [19] and wildtype mice [20,21] but not in Smad3 knockout mice [22]. In 
the current report, we subjected wildtype mice to lung injury by intratracheal administration 
of adenoviral vectors expressing the firefly gene-luciferase(Ad-Luc) or overexpressing TGF-
β (Ad-TGF-β).
We then mimicked the clinical setting wherein IPF patients present themselves with lung 
fibrosis and used a therapeutic strategy (Figures 1A-1F) as reported previously [3,4,16,17]. 
At two weeks after the onset of fibrosis, we then silenced the gene expression of C3ar or 
C5ar using oropharyngeal instillation of naked siRNA. Histopathological examination of 
mice exposed to Ad-TGF-β revealed significant fibrosis (Figure 1C; upper panels) and 
collagen deposition as shown by Masson’s trichrome staining (Figure 1C; lower panels). 
Further, quantitative analysis of collagen content was significantly higher as shown by 
hydroxyproline levels (Figure 1B) and mRNA expression of Col1a1 and Col1a2 (Figure 
1D). Interestingly, Ad-TGF-β-injured mice that received siRNA specific to either C3ar or 
C5ar showed a near normal lung architecture and significantly lower collagen deposition and 
collagen content. Collectively, our results show a protection against TGF-β-induced lung 
fibrosis with blockade of C3a or C5a signaling on binding to their respective receptors. In 
Figure 1E, we show that the siRNA specific to C3ar and C5ar1 instilled into these lungs 
injured with the lentiviral bvectors overexpressing TGF-β, were indeed effective in silencing 
the C3aR and C5aR protein expressions. These data suggest that either the two pathways are 
triggered in parallel or that TGF-β is upstream of signaling due to C3a or C5a.
RNA interference suppresses local complement activation
We have previously demonstrated that local C3a and C5a levels are higher due to bleomycin 
injury at day 14 [4] and that genetic silencing of their receptors suppressed bleomycin-
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induced local C3a, C5a and soluble C5b-9 levels [4]. We have also observed a suppression 
of these complement components due to bleomycin injury in IL-17A deficient mice [3]. 
Furthermore, we had reported that IL-17A-mediates epithelial injury via TGF-β during 
bronchiolitis obliterans [1]. We next sought to define the hierarchical role of C3a and C5a on 
binding to their respective receptors in a TGF-β-induced murine model of lung fibrosis. 
Since IPF patients present with established fibrosis, we simulated the clinical condition and 
examined the effects of targeted genetic silencing of C3ar and C5ar in a significantly scarred 
lung. Using the treatment regimen shown in Figure 1A, the mice were subjected to 
oropharyngeal instillation of siRNA specific to C3ar and C5ar at day 14-a time point when 
the lungs are significantly fibrotic. Increased levels of C3a and C5a in the BALF were 
reported in transfusion-related acute lung injury [23] and chronic rejection post-lung 
transplant [24]. Elevated tissue deposition of C5b9 was reported during acute rejection phase 
post-lung transplant [25]. Our studies show that active C3a and C5a levels were higher in the 
BALF of mice exposed to adenoviral vectors overexpressing TGF-β. However, genetic 
silencing of C3ar or C5ar suppressed the local levels of C3a and C5a as shown in Figures 2A 
and 2B. These results suggest that TGF-β-induced activation of the complement cascade is 
attenuated by diminishing the expression of the receptors for C3a and C5a possibly via a 
feedback loop.
Potential mechanisms underlying TGF-β-induced complement activation
We next investigated the potential mechanisms underlying TGF-β-induced complement 
activation in response to therapeutic gene silencing of C3ar or C5ar. We had previously 
reported that C3a and C5a each downregulate the mRNA expression of Smad7 and that 
TGF-β upregulated the protein expressions of both C3aR and C5aR in primary normal 
human SAECs [2]. We therefore hypothesized that siRNA specific genetic silencing of C3ar 
or C5ar will prevent C3a or C5a-mediated downregulation of Smad7 expression. Figure 3A 
shows a significant recovery of TGF-β-induced downregulation of Smad7 mRNA expression 
in fibrotic murine lungs due to genetic silencing of C3ar or C5ar. Our prior reports show that 
TGF-β mediates the loss of membrane-bound DAF from SAECs. Further, we had reported 
that loss of DAF leads to epithelial apoptosis [2]. Since DAF is a GPI-anchored membrane-
bound molecule, we hypothesized that genetic silencing of C3ar or C5ar may stem the extent 
of cleavage or the release of DAF onto the lumen of the alveoli and the airways. In our 
studies, we subjected acellular BALF of equal protein concentrations to immunoblotting 
(Figure 3B) and detected highest amount of DAF cleavage or release in TGF-β-
overexpressing lungs. This release was significantly suppressed due to genetic silencing of 
C3ar or C5ar as demonstrated by the densitometric analyses of the band intensity. Our 
results herein suggest that genetic inhibition of signaling due to C3a or C5a may likely 
protect against TGF-β-induced lung fibrosis by preventing further downregulation of Smad7 
due to the additive effects of complement fragments and by preventing epithelial injury due 
to loss of DAF.
We had previously reported that pharmacologic blockade of C3aR and C5aR prevents the 
loss of the complement inhibitors-CD46 and DAF [2]. In this report, in Figure 3C we show 
that indeed with genetic silencing of C3ar or C5ar, we are able to recapitulate this effect in 
primary normal human SAECs. We also show effectiveness and specificity of the siRNA by 
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showing the lack of protein expression of the respective receptor. Since we had previously 
shown that C3a specifically had upregulated the mRNA expression of TGF-β, we next asked 
the question if C3a causes loss of DAF directly or by indirectly by inducing the release of 
TGF-β and hence mediate the cleavage or release of DAF. Towards this end, in Figure 3D, 
we show that pharmacologic blockade the tyrosine kinase of the receptor type I for TGF-β, 
i.e. ALK5, effectively prevents the loss of membrane-bound cellular DAF at 24 h. We next 
investigated this effect in normal primary human alveolar type II epithelial cells (hAECs). 
Our prior studies show that IL-17A mediates loss of cellular DAF within 4 h in hAECs [3]. 
We therefore investigated the loss of cellular DAF with blockade of receptors of C3a 
(C3aRA) and TGF-β (ALK5 In) in parallel to assess the extent of protection. We 
hypothesize that C3a-mediated loss of DAF will be prevented to a higher extent by blocking 
C3aR since signaling due to C3a and TGF-β is suppressed. The lower panels in Figure 3D 
show that both “C3aRA” and “ALK5 In” have similar efficacies in preventing C3a-mediated 
loss of DAF. Thus, our in vitro studies suggest that while it is likely that C3a-mediated loss 
of DAF may be dependent on TGF-β, they may also be functioning via parallel pathways. 
Collectively, our in vivo and in vitro observations indicate that TGF-β-induced lung fibrosis 
activates complement and this is blocked by recovering the expression levels of the 
inhibitors of either pathways, i.e. SMAD7 and DAF. It is also likely that TGF-β may be 
upstream of complement and that complement may function in parallel to TGF-β signaling 
pathway.
Relative miRNA regulation by TGF-β, C3a or C5a in normal primary human small airway 
epithelial cells
Key regulatory roles for miRNA either due to upregulation of miRNAs including miR-21 
[14], miR-154, miR-134, miR-299-5p, miR-410, miR-382, miR-409-3p, miR-487b, miR-31, 
and miR-127 [26], miR-145 [27], miR-199-5p [13], or due to the downregulation of 
miRNAs including miR-let-7d [15], miR-29 [11], miR-200a/b/c [28], miR-17~92 [29], have 
been detected in IPF lungs or have been implicated in the pathogenesis of lung fibrosis. 
While most of the miRNA regulation is reported based on TGF-β studies, very few are 
reported in response to C3a [30] or C5a [31] in neuropathy. Therefore, we asked the 
question if there are any overlaps in the miRNA regulation due to TGF-β, C3a or C5a and 
thus yield possible post-transcriptional targets related to epithelial functions or injury and 
those related to lung fibrosis. We cultured normal primary human SAECs to 70% confluence 
and exposed them to exogenous doses of TGF-β or C3a or C5a in parallel for 24 h. We used 
SAECs from at least five different donors to yield biological replicates. We then isolated 
RNA from the treated cells and subjected them to Affymetrix array analyses. Of the 
complete human genome, the chip presented a regulation profile of 52 miRNAs. We used a 
cut-off fold-change value of ~± 1.35 for the regulated miRNAs. From our analyses of the 
three agonists, we observed changes in 33 miRNAs due to at least one of the agonists and 
this is presented in Table 1. In response to TGF-β, a total of 27 miRNAs were modulated 
with upregulation of 18 miRNAs and downregulation of nine miRNAs. In response to C3a, a 
total of four miRNAs were modulated with upregulation of two miRNAs and 
downregulation of two miRNAs. In response to C5a, a total of three miRNAs were 
modulated and all of them were downregulated. It should be noted that miR-548AC was 
downregulated by both C3a and TGF-β and is implicated in tumor biology. C5a shares a 
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common miRNA with TGF-β: downregulation of miRNA-200C, which is implicated in lung 
fibrosis, albeit our studies do not show a significant fold change. Interestingly, in response to 
TGF-β, three (miR-21, miR-31HG, miR-503) of the 27 upregulated miRNAs are reportedly 
implicated in the pathogenesis of lung fibrosis. Fold changes in the other miRNAs are 
presented in Table 1. Our data suggest possible overlap in post-transcriptional regulation of 
complement with TGF-β in the pathogenesis of lung fibrosis.
Discussion
Our results presented herein provide new insights on the hierarchical relationship between 
the complement cascade and TGF-β signaling. Our results suggest that TGF-β-induced lung 
fibrosis is arrested by blocking complement signaling. We also observed that TGF-β-
induced local complement activation is suppressed by blocking complement signaling. 
Furthermore, TGF-β-induced loss of inhibitors of the two cascades, i.e. Smad7 (negative 
modulator of TGF-β) and DAF (early inhibitor of the complement cascade) is recovered. In 
vitro, we demonstrate that TGF-β-induced loss of DAF is prevented by RNAi-mediated 
silencing of the receptors to complement. Blockade of the TGF-β receptor kinase prevented 
the loss of C3a-mediated loss of DAF. Interestingly, both C3a and C5a share miRNA 
regulation in common with TGF-β of those common with epithelial proliferation, fibrosis 
and tumor biology. Cumulatively, our data suggest that while complement signaling may not 
be upstream of that of TGF-β, they share parallel mechanisms in mediating lung fibrosis.
It is well-established that genetic silencing or the pharmacologic blockade of the receptors 
for C3a or C5a results in suppression of the pro-inflammatory/pro-fibrotic molecule, TGF-β, 
in experimental models of lung fibrosis [4], sepsis [32], hepatic metastases of colon cancer 
[33] and immunoglobin A nephropathy [34].
Although each of these reports had investigated and reported the effects of blocking 
complement on TGF-β, none of these reports had interrogated the hierarchical relationship 
of complement and TGF-β. Based on our prior report [4], we hypothesized that since genetic 
silencing of the receptors for C3a or C5a suppresses TGF-β-related signaling and hence 
bleomycin-induced lung fibrosis, then genetic silencing of the receptors for C3a or C5a 
should not protect against TGF-β-induced lung fibrosis. However, we detected an arrest in 
lung fibrosis. Our data suggest that complement activation most likely enhances TGF-β 
signaling and shares signaling pathways and miRNA regulation related to lung fibrosis. Lam 
et al [21] had reported that deficiency of Wnt co-receptor, lrp5, resulted in a reduced 
production of bleomycin-induced TGF-β in the lungs. Therefore, they had hypothesized that 
if lrp5 were upstream of TGF-β, then there should not be any protection in the lrp5-deficient 
mice in TGF-β-induced lung fibrosis and reported observations that supported their 
hypothesis. In our studies, we observed a combined recovery of both Smad7 and DAF-the 
inhibitors of TGF-β and the complement cascade, respectively. This would explain the 
reason underlying the protection against TGF-β-induced lung fibrosis. To the best of our 
knowledge, this is the first report to demonstrate the hierarchical relationship of a major 
innate immune pathway-the complement cascade, when activated by the pro-fibrotic 
cytokine-TGF-β. Our studies suggest that these two cascades mediate fibrosis by functioning 
in parallel.
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We had recently reported higher hemolytic activity in IPF patients [3]. Recent clinical 
reports indicate that targeting the complement cascade is gaining traction, e.g. C3 
(compstatin/POT-4 peptide) [35], C5 antibody (Soliris; Alexion Pharmaceuticals) [36], 
Factor D (TNX-234 antibody) [37], C5aR1 inhibitor, C1-INH (various manufacturers) in 
treating Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, 
ARMD, gastrointestinal injury-related GVHD, C3 nephropathy, amyotrophic lateral 
sclerosis and other severe disorders. Our results in this report show that limiting complement 
activation may be a promising therapeutic strategy against TGF-β-induced lung fibrosis and 
is consistent with the report on the bleomycin injury model [4]. Therefore, the number of 
complement inhibitors previously used in clinical trials targeting other diseases can now be 
extended as a therapy for lung fibrosis.
Since the TGF-β/Smad2/3 and bone morphogenic proteins [4,7]/Smad1 signaling pathway 
has been implicated in clinical IPF [38] and in the murine bleomycin model of IPF [16], the 
effect of complement inhibition in Smad regulation was investigated. TGF-β1 signaling 
occurs via Type I and II receptor-mediated phosphorylation, whereby activated TGF-β1 
receptor I phosphorylates Smad2 and Smad3 (receptor Smads, or R-Smads) at C-termini. R-
Smads then complex with other molecules, translocate to the nucleus, and activate 
extracellular matrix gene transcription, enhancing fibrosis. R-Smads, particularly at the 
linker region, have also been shown to be phosphorylated by MAPK. R-Smad 
phosphorylation is antagonized by inhibitory Smad6 [39] and Smad7 [16] overexpression, 
which down-regulates TGF-β-induced activity and fibrosis. Smad6 and Smad7 are known 
antagonists of TGF-β signaling [40,41]. To our knowledge, this is the first report 
demonstrating the recovery of the inhibitory Smad7 via the suppression of complement 
activity. We next interrogated the inhibitor of the complement cascade-DAF. DAF is a 
glycosylphosphatidylinositol (GPI)-anchored membrane protein that restricts the synthesis 
of C3 and C5 convertases, and minimizes deposition of C3 and generation of C3a, C5a and 
C5b-9 [42]. It has a serine/threonine-enriched spacer domain and four complement control 
protein (CCP) repeats, which are tethered to the cell membrane by the GPI anchor [42]. 
When DAF binds to C3, the CCP2/3 domains prevent C3 formation and accelerate the decay 
of the C3 convertases C3bBb (alternative pathway) and C4b2a (classical and mannose-
binding lectin pathways) [43]. Our data indicates that release of DAF onto the airway lumen 
due to TGF-β-induced lung injury is prevented by silencing the expression of the 
complement receptors. We also demonstrate this effect in vitro. This is consistent with our 
previous findings using pharmacologic blockade of TGF-β-induced loss of DAF in vitro.
Finally, we also interrogated the effects of blocking the TGF-β type I receptor-ALK5 
(Alkivin like 5). Interestingly, we observed that regardless of a longer (48 h-SAECs) or a 
shorter (6h-AECs) exposure of C3a, pharmacologic blockade of ALK5 prevented the loss of 
DAF. This indicates a possibility of an autocrine effect, wherein C3a may induce loss of 
DAF via TGF-β. While we have established in our prior report that SAECs synthesize TGF-
β transcripts at 16–24 h in response to C3a, it is unlikely that TGF-β transcripts are made as 
early as 4–6 h in AECs. Overall, our data provide mechanistic insights underlying 
complement inhibition in arresting TGF-β-induced lung fibrosis.
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Till date, the miRNA studies have focused on regulation due to TGF-β in the pathogenesis 
of lung fibrosis. To the best of our knowledge, our results are the first to interrogate the 
effect of C3a or C5a on miRNA regulation in normal primary human small airway epithelial 
cells. While the optimal temporal regulation of the miRNA warrants more stringent 
investigation, our results interestingly show that at 24 h, all three agonists upregulated 
miR-494 which has been implicated in the upregulation of ATF6 [44] or activated 
transcription factor isoform 6, a known endoplasmic reticular (ER) stress-related protein. ER 
stress has been implicated in epithelial injury, specifically in the lungs of patients with IPF 
[3,45,46]. While TGF-β signaling has been implicated in the downregulation of mir-200c 
and this was also observed in the lungs of IPF patients [28], interestingly our studies in 
normal primary human SAECs detected C5a-mediated downregulation of this miRNA. 
However, we detected upregulation of other classic miRNAs consistent with previous 
findings that they are implicated in lung fibrosis such as miR-21 [14], miR-31HG [26] and 
miR-503 [47,48]. Interestingly polymorphism in miR-4302 upregulated by C3a was 
associated with greater survival in lung cancer [49]. Our studies indicate that the 
complement cascade shares some miRNA regulation in the pathogenesis of lung fibrosis.
Our study has some potential limitations. First, although we have shown that TGF-β-induced 
lung fibrosis activates complement, we have not shown the specific mechanisms inducing 
the release of membrane-bound DAF are unknown. Secondly, the miRNA regulations are 
from 5 different normal donor lungs and the temporal responses and the contextual functions 
are yet to be characterized. The above limitations will shape our prospective studies.
Conclusion
In conclusion, our results suggest that the therapeutic blockade of C3a and C5a from binding 
to their respective receptors, C3aR and C5aR, using siRNA, arrests the progression of TGF-
β-induced lung fibrosis by limiting complement activation. Additionally, the expression of 
the inhibitors of the two cascades i.e., SMAD7 and DAF, are restored, which will thus limit 
further signaling due to these pro-fibrotic mediators. Finally, we present some evidence 
showing that the two cascades share overlapping miRNA regulations which are potentially 
implicated in the pathogenesis of lung fibrosis.
Acknowledgments
Funding Support Sources
NIH-NHLBI-R01-HL109288 (RV)
Abbreviations
Ad-Luc Adenoviral Vector Expressing the Firefly Gene-Luciferase
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C3aR C3a Receptor
C5aR C5a Receptor
Col(I) Collagen Type I
DAF Decay Accelerating Factor
GADPH Glyceraldehyde-3-Phosphate Dehydrogenase
PBS Phosphate Buffered Saline
IT Intratracheal
IP Intraperitoneal
Col1a1 Collagen Type I Alpha 1 Chain
Col1a2 Collagen Type I Alpha 2 Chain
H&E Hematoxylin and Eosin
BALF Bronchoalveolar Lavage Fluid
C5b-9 Terminal Complement Complex
IPF Idiopathic Pulmonary Fibrosis
IUSM Indiana University School of Medicine
PCR Polymerase Chain Reaction
RNA Ribonucleic Acid
qPCR Quantitative (Real-Time) Polymerase Chain Reaction
siRNA Small Interference Ribonucleic Acid
φ siRNA Non-Targeting siRNA
TGFβ1 Transforming Growth Factor Beta Isoform 1
PFU Plaque Forming Units
AU Arbitrary Units
RQ Relative Quantification
FDR False Discovery Rate
C3aRA C3a Receptor Antagonist
ALK5 In Alkivin-like 5 Inhibitor
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Figure 1. 
(A) This is a schematic model representing C57/BL6 mice, which were intratracheally 
instilled with adenoviral vectors either expressing murine TGF-β or the firefly gene-
Luciferase (Day 0: 1 × 109 PFU/mL). At day 14, mice were administered 50 μg of siRNA 
specific to C3ar or C5ar. At day 28, mice were sacrificed. (B) Left lungs were acid digested 
and the hydrolysates were analyzed for hydroxyproline. Values: Means ± SEM. (n=10-12 
per group). One-way ANOVA, Bonferroni. (C) Histopathological exam using H&E and 
trichrome staining showed that bleomycin-induced fibrosis and collagen deposition was 
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attenuated by the limiting complement activation. Scale=100 μm. This was confirmed by 
analyzing the transcript levels of col1a1 (D) and col1a2 (E,F) in the lung. One-way 
ANOVA, Newman-Keuls. Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. 
Results are representative of three independent experiments.
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Figure 2. 
RNA interference suppresses local complement activation. BALF collected from Figure 1 
were analyzed for C3a (A) and C5a (B) levels in the lung by ELISA. Values: Means ± SEM. 
(n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: 
p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.
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Figure 3. 
Potential mechanisms underlying RNAi mediated gene silencing of C3aR or C5aR in TGF-
binduced lung fibrosis. (A) Whole lung homogenates from Figure 1 were analyzed for 
Smad7 transcripts via qPCR. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, 
Newman-Keuls. (B) BALF collected from Figure 1 were analyzed for equal protein 
concentrations and subjected to immunoblotting against antibodies for DAF. Band intensities 
were analyzed by densitometry. Values: Means ± SEM. (n=3-4 per group). One-way 
ANOVA, Bonferroni. Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results 
are representative of three independent experiments. (C) Normal primary human SAECs 
were subjected to siRNA transfections of non-targeting control (φ) siRNA or specific to 
C3ar or C5ar for 24 h. The cells were then exposed to TGF-β for 48h. Lysates were 
subjected to immunoblotting against DAF, C3aR and C5aR (loading control: β-actin). (D) 
Normal primary human SAECs were pre-treated with ALK5 inhibitor for 1 h and then 
treated with C3a for 24 h. Lysates were subjected to immunoblotting against DAF (loading 
control: β-actin). Normal primary human AECs were pre-treated with inhibitors specific to 
ALK5 and C3aR for 1 h and then treated with C3a for 6h. Lysates were subjected to 
immunoblotting against DAF (loading control: β-actin).
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